Article Trunk



Chemistry / M2 Pharma, “Cynata reports positive 28-day results in latest GvHD trial.”

06.21.2018 · Posted in Uncategorized
M2 PHARMA-June 21, 2018-Cynata reports positive 28-day results in latest GvHD trial (C)2018 M2 COMMUNICATIONS Stem cell and regenerative medicine specialist Cynata Therapeutics Ltd (ASX: CYP) has recorded positive 28-day safety and efficacy data from Cohort B of its Phase 1 clinical trial of CYP-001 in steroid-resistant acute graft-versus-host disease (GvHD), the Australian company...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: